The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $40.97

Today's change0.00 0.00%
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $40.97

Today's change0.00 0.00%
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.

Powershares Dynamic Biotechnology and Genome Portfolio closed at (U.S.)$40.97.

Over the last five days, shares have lost 0.87% and are down 18.90% for the last year to date. This security has underperformed the S&P 500 by 34.82% during the last year.

Key company metrics

  • Open(U.S.) $40.81
  • Previous close(U.S.) $40.97
  • High(U.S.) $41.24
  • Low(U.S.) $40.51
  • Bid / Ask-- / --
  • YTD % change-18.90%
  • Volume9,735
  • Average volume (10-day)17,917
  • Average volume (1-month)29,190
  • Average volume (3-month)35,750
  • 52-week range(U.S.) $34.02 to (U.S.) $56.90
  • Beta1.29
  • Trailing P/E3.15×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield1.09%
  • Trailing EPS(U.S.) $13.01
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,132.76%

Based on its net profit margin of 2,132.76%, Powershares Dynamic Biotechnology and Genome Portfolio is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.06%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

    No News Results.

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedApr 30, 201504/30/2015Oct 31, 201410/31/2014Apr 30, 201404/30/2014Oct 31, 201310/31/2013
Revenue2320
Total other revenue--------
Total revenue2320
Gross profit1210
Total cost of revenue1110
Total operating expense1111
Selling / general / administrative0000
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income1200
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax28892740
Income after tax28892740
Income tax, total----00
Net income28892740
Total adjustments to net income--------
Net income before extra. items28892740
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items28892740
Inc. avail. to common incl. extra. items28892740
Diluted net income28892740
Dilution adjustment--------
Diluted weighted average shares119117
Diluted EPS excluding extraordinary itemsvalue per share2.6710.332.545.37
Dividends per sharevalue per share0.000.280.000.00
Diluted normalized EPSvalue per share2.6710.332.545.37